An updated review of human monkeypox disease: A new potential global hazard

Monkeypox, a recently developed viral infectious disease, has become a concern for the general public. This predicament has emerged because of the increased incidence of human monkeypox infections. It was previously a serious zoonotic virus native to just sections of Central and Western Africa and was never recorded outside endemic areas. In this review, the author presented considerable data on this disease and offered a detailed summary of MPXV. More recently, as of October 27, 2022, Monkeypox cases spread quickly across the globe, infecting 76713 people globally, with the majority of cases from Europe, the United Kingdom, North and South America, Asia, and the Middle East. By October 27, 2022, the disease had spread to almost 109 countries. In the United States, there were 28244 (36.82%) cases of Monkeypox; in Brazil, 9045 (11.79%); in Spain, 7317 (9.53%); in the United Kingdom, 3698 (4.82%); in France, 4094 (5.34%); in Germany, 3662 (4.77%); in Colombia, 3298 (4.29%); in Peru, 3048 (3.92%); in Canada, 1436 (1.87%); in Belgium, 786 (1.02%) and Portugal, 944 (1.23%). In terms of the overall number of deaths, 36 deaths were reported, with the maximum eight deaths being from Brazil (22.22%), seven from Nigeria (19.44%), and six deaths from the United States (16.67%). However, human Monkeypox epidemiological trends are rapidly changing, leaving endemic areas and moving to non-endemic countries. Therefore, international health authorities must implement priority-based preventive measures to prevent the spread of Monkeypox infection worldwide.